Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27707
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThia, Brandon-
dc.contributor.authorMcGuinness, Myra B-
dc.contributor.authorEbeling, Peter R-
dc.contributor.authorKhong, Jwu Jin-
dc.date2021-10-06-
dc.date.accessioned2021-10-11T04:12:44Z-
dc.date.available2021-10-11T04:12:44Z-
dc.date.issued2022-
dc.identifier.citationInternational ophthalmology 2022-03; 42(3): 863-870en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/27707-
dc.description.abstractThe Immulite® thyroid stimulating immunoglobulin (TSI) immunoassay is a relatively new commercial assay that has shown good diagnostic accuracy in Graves' hyperthyroidism (GH). However, its clinical utility in thyroid-associated orbitopathy (TAO) is less clear. The purpose of this study was to assess the diagnostic accuracy of the Immulite® TSI immunoassay for TAO and investigate the associations between TSI and other clinical measures. One hundred and forty patients that had been diagnosed with GH within the previous 12 months were recruited. Identification and grading of TAO were performed at enrolment and serum samples were analysed using the Immulite® TSI immunoassay. Of the 140 participants recruited, 75 (53.6%) had TAO. Age, sex and time since GH diagnosis were similar between those with and without TAO (p ≥ 0.300). TSI level tended to decrease with increasing time from GH diagnosis (Spearman's ρ - 0.28, 95% CI - 0.43, - 0.12). TSI levels were higher among those with than those without TAO (median 4.0 vs. 2.7 IU/L, respectively, p = 0.037). There was no correlation between TSI level and inflammatory index score (ρ = 0.14, 95% CI - 0.03, 0.30) or clinical severity (p = 0.527) among those with TAO. TSI level showed poor diagnostic accuracy for TAO (area under the receiver operating characteristic curve 0.60, 95% CI 0.51, 0.70). Although Immulite® TSI level was higher in the presence of TAO, it showed poor diagnostic accuracy and no correlation with clinical markers of TAO severity or activity.en
dc.language.isoeng-
dc.subjectGraves’ orbitopathyen
dc.subjectImmunoassayen
dc.subjectThyroid stimulating immunoglobulinen
dc.subjectThyroid-associated orbitopathyen
dc.titleDiagnostic accuracy of Immulite® TSI immunoassay for thyroid-associated orbitopathy in patients with recently diagnosed Graves' hyperthyroidism.en
dc.typeJournal Articleen
dc.identifier.journaltitleInternational Ophthalmologyen
dc.identifier.affiliationCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, 3002, Australiaen
dc.identifier.affiliationDepartment of Medicine, Monash Medical Centre, School of Clinical Sciences, Monash University, Clayton, VIC, 3168, Australiaen
dc.identifier.affiliationOrbital, Plastic and Lacrimal Unit, The Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, 3002, Australiaen
dc.identifier.affiliationOphthalmologyen
dc.identifier.affiliationCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, 3010, Australiaen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.doi10.1007/s10792-021-02052-0en
dc.type.contentTexten
dc.identifier.orcid0000-0002-6074-4226en
dc.identifier.pubmedid34613563-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.